二甲双胍延缓多囊肾病肾功能下降的实施研究(IMPEDE-PKD):一项评估二甲双胍长期延缓常染色体显性多囊肾病患者肾功能下降速率的III期多中心随机安慰剂对照试验的研究方案
IMPEDE-PKD是一项前瞻性、多中心、国际、双盲、随机对照试验,在成人常染色体显性多囊肾病(ADPKD)患者中比较二甲双胍与安慰剂。计划从2022年11月起在全球招募1174名受试者,经过10周缓释二甲双胍剂量递增至最大2000 mg的导入期后,按1:1随机分配接受二甲双胍或安慰剂并随访2年,主要结局为估算肾小球滤过率变化所测的肾功能下降速率。
要点
- ADPKD是全球启动透析的第四大常见原因,亟需延缓肾功能丧失的治疗。
- IMPEDE-PKD计划在全球招募1174名成人ADPKD患者,随机分配二甲双胍或安慰剂并随访2年。
- 主要结局为估算肾小球滤过率变化所测的肾功能下降速率。
核心结论
- 若被证实有效,二甲双胍将作为一种广泛可及且可负担的治疗选择,对ADPKD患者的健康产生积极影响。
研究设计与样本
- IMPEDE-PKD是一项前瞻性、多中心、国际、双盲、随机对照试验,在成人ADPKD患者中比较二甲双胍与安慰剂。
- 计划从2022年11月起在全球参与肾脏中心招募共1174名受试者,来自澳大利亚、英国、新西兰、印度、香港、东南亚和欧洲。
- 经过10周缓释二甲双胍剂量递增至最大2000 mg的导入期后,受试者按1:1随机分配接受二甲双胍或安慰剂并随访2年。
主要发现
- 主要结局为估算肾小球滤过率变化所测的肾功能下降速率。
- 次要结局包括ADPKD进展的其他临床标志物(白蛋白尿、肾衰竭发生)、死亡、健康相关生活质量、疼痛、药物副作用、耐受性和成本效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common reason for commencement of dialysis globally. There is an urgent need for treatments to slow the loss of kidney function and prevent complications in people with ADPKD. A growing body of evidence suggests metformin may have a therapeutic role in slowing cyst progression in ADPKD. METHODS: IMPEDE-PKD is a prospective, multicentre, international, double-blind, randomized controlled trial of metformin versus placebo in adults with ADPKD. From November 2022, a total of 1174 participants will be targeted for recruitment globally, from participating kidney units in Australia, the UK, New Zealand, India, Hong Kong, South-East Asia and Europe. Following a 10-week run-in phase of extended-release metformin up-titrated to a maximum dose of 2000 mg, participants will be randomized 1:1 to receive either metformin or placebo and followed for 2 years. The primary outcome will be the rate of kidney function decline measured as a change in the estimated glomerular filtration rate. Secondary outcomes include other clinical markers for ADPKD progression (albuminuria, development of kidney failure), mortality, health-related QOL, pain, medication side effects, tolerability and cost-effectiveness. DISCUSSION: If proven effective, metformin would positively impact the well-being of people with ADPKD as a treatment option that is widely available and affordable. TRIAL REGISTRATION: CLINICALTRIALS: gov NCT04939935. Registered on 25 June 2021.
引用
- Pierre KS, El-Damanawi R, Johnson DW, et al. Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. Trials. 2025. PMID: 40855441. doi:10.1186/s13063-025-09010-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。